| For: | Riveiro-Barciela M, Marcos-Fosch C, Martinez-Valle F, Bronte F, Orozco O, Sanz-Pérez I, Torres D, Salcedo MT, Petta S, Esteban R, Craxi A, Buti M. Naïve hepatitis B e antigen-negative chronic hepatitis B patients are at risk of carotid atherosclerosis: A prospective study. World J Gastroenterol 2021; 27(30): 5112-5125 [PMID: 34497439 DOI: 10.3748/wjg.v27.i30.5112] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v27/i30/5112.htm |
| Number | Citing Articles |
| 1 |
Qi Zhang, Cancong Shen, Lei Zhang, Maiqiu Wang. Causal Relationship between Chronic Hepatitis B and Stroke in East Asians: A Mendelian Randomization Study. Journal of Cardiovascular Development and Disease 2024; 11(8) doi: 10.3390/jcdd11080247
|
| 2 |
V.B. Stetseviat, N.M. Voronych-Semchenko, M.M. Bahrii, T.V. Huranych. PREDICTORS OF HEPATOCYTES CYTOLYSIS OF INSULIN RESISTANT RATS UNDER CONDITIONS OF PRE- AND POSTNATAL IODINE DEFICIENCY. Fiziolohichnyĭ zhurnal 2023; 69(3) doi: 10.15407/fz69.03.010
|
| 3 |
Qian Li, Yihui Chai, Wen Li, Liancheng Guan, Yizi Fan, Yunzhi Chen. Mechanism of Simiao Decoction in the treatment of atherosclerosis based on network pharmacology prediction and molecular docking. Medicine 2023; 102(36) doi: 10.1097/MD.0000000000035109
|
| 4 |
琊芸 徐. Prevalence and Impact of Nonalcoholic Fatty Liver Disease in Patients with Chronic Hepatitis B. Advances in Clinical Medicine 2023; 13(07) doi: 10.12677/ACM.2023.1371563
|
| 5 |
R.N. Mustafin. Prospects for the use of statins in antiviral therapy. Clinical Microbiology and Antimicrobial Chemotherapy 2023; 25(1) doi: 10.36488/cmac.2023.1.56-67
|
| 6 |
Atefe Ghamar Talepoor, Mehrnoosh Doroudchi. Immunosenescence in atherosclerosis: A role for chronic viral infections. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.945016
|
| 7 |
Ningxin Zhang, Zhongwei Xu, Fei Lin, Haozhi Fan, Dehong Zhou, Shiqiu Zheng, Peng Jin, Huiquan Gu, Chengxiao Yu, Longfeng Jiang. Metabolic dysfunction-associated steatotic liver disease in chronic hepatitis B patients: risks of severe liver disease and cardiovascular disease. Frontiers in Cellular and Infection Microbiology 2026; 16 doi: 10.3389/fcimb.2026.1806927
|
| 8 |
Ivan Ranković, Vladimir Milivojević, Aleksandra Pavlović Marković, Mihailo Bezmarević. Interplay between chronic hepatitis B and atherosclerosis: Innovative perspectives and theories. World Journal of Gastroenterology 2022; 28(4): 497-499 doi: 10.3748/wjg.v28.i4.497
|
| 9 |
Shana A.B. Burrowes, Erin Zisman, Lori E. Fantry, Quoc Bui, Angela Wu, John Sorkin, Michael Miller, Shashwatee Bagchi. Changes in Atherosclerotic Cardiovascular Disease Risk Scores in a Predominantly Black Cohort with HIV and Associated Comorbidities: A Preliminary Study. Cardiology 2024; doi: 10.1159/000540526
|
| 10 |
Xin Cai, Shi Peng, Xuan Xiao, Zhaoyang Huang, Pingan Zhang. Serum ApoB/ApoA1 ratio in patients with CHB and the occurrence of HBV related cirrhosis and HBV related hepatocellular carcinoma. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-61820-x
|
| 11 |
Laurent Lam, Marc Bourlière, Stanislas Pol, Fabrice Carrat. Impact of Nucleos(t)ide Analogs on Major Clinical Outcomes in Patients With Chronic Hepatitis B: A 10‐Year French Nationwide Cohort Study. Alimentary Pharmacology & Therapeutics 2025; 61(5) doi: 10.1111/apt.18462
|